Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. / Serruys, Patrick W; Onuma, Yoshinobu; Ormiston, John A; de Bruyne, Bernard; Regar, Evelyn; Dudek, Dariusz; Thuesen, Leif; Smits, Pieter C; Chevalier, Bernard; McClean, Dougal; Koolen, Jacques; Windecker, Stephan; Whitbourn, Robert; Meredith, Ian; Dorange, Cécile; Veldhof, Susan; Miquel-Hebert, Karine; Rapoza, Richard; García-García, Hector M.

In: Circulation, Vol. 122, No. 22, 30.11.2010, p. 2301-12.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Serruys, PW, Onuma, Y, Ormiston, JA, de Bruyne, B, Regar, E, Dudek, D, Thuesen, L, Smits, PC, Chevalier, B, McClean, D, Koolen, J, Windecker, S, Whitbourn, R, Meredith, I, Dorange, C, Veldhof, S, Miquel-Hebert, K, Rapoza, R & García-García, HM 2010, 'Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes', Circulation, vol. 122, no. 22, pp. 2301-12. https://doi.org/10.1161/CIRCULATIONAHA.110.970772

APA

Serruys, P. W., Onuma, Y., Ormiston, J. A., de Bruyne, B., Regar, E., Dudek, D., Thuesen, L., Smits, P. C., Chevalier, B., McClean, D., Koolen, J., Windecker, S., Whitbourn, R., Meredith, I., Dorange, C., Veldhof, S., Miquel-Hebert, K., Rapoza, R., & García-García, H. M. (2010). Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation, 122(22), 2301-12. https://doi.org/10.1161/CIRCULATIONAHA.110.970772

CBE

Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Miquel-Hebert K, Rapoza R, García-García HM. 2010. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation. 122(22):2301-12. https://doi.org/10.1161/CIRCULATIONAHA.110.970772

MLA

Vancouver

Author

Serruys, Patrick W ; Onuma, Yoshinobu ; Ormiston, John A ; de Bruyne, Bernard ; Regar, Evelyn ; Dudek, Dariusz ; Thuesen, Leif ; Smits, Pieter C ; Chevalier, Bernard ; McClean, Dougal ; Koolen, Jacques ; Windecker, Stephan ; Whitbourn, Robert ; Meredith, Ian ; Dorange, Cécile ; Veldhof, Susan ; Miquel-Hebert, Karine ; Rapoza, Richard ; García-García, Hector M. / Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. In: Circulation. 2010 ; Vol. 122, No. 22. pp. 2301-12.

Bibtex

@article{5a2dca3d47534562a15e9721b0e831b9,
title = "Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes",
abstract = "The first generation of the bioresorbable everolimus drug-eluting vascular scaffold showed signs of shrinkage at 6 months, which largely contributed to late luminal loss. Nevertheless, late luminal loss was less than that observed with bare metal stents. To maintain the mechanical integrity of the device up to 6 months, the scaffold design and manufacturing process of its polymer were modified.",
keywords = "Absorbable Implants, Aged, Coronary Angiography, Coronary Stenosis, Coronary Vessels, Drug-Eluting Stents, Female, Follow-Up Studies, Humans, Male, Middle Aged, Polymers, Retrospective Studies, Sirolimus, Time Factors, Tissue Scaffolds, Tomography, Optical Coherence, Treatment Outcome",
author = "Serruys, {Patrick W} and Yoshinobu Onuma and Ormiston, {John A} and {de Bruyne}, Bernard and Evelyn Regar and Dariusz Dudek and Leif Thuesen and Smits, {Pieter C} and Bernard Chevalier and Dougal McClean and Jacques Koolen and Stephan Windecker and Robert Whitbourn and Ian Meredith and C{\'e}cile Dorange and Susan Veldhof and Karine Miquel-Hebert and Richard Rapoza and Garc{\'i}a-Garc{\'i}a, {Hector M}",
year = "2010",
month = nov,
day = "30",
doi = "10.1161/CIRCULATIONAHA.110.970772",
language = "English",
volume = "122",
pages = "2301--12",
journal = "Circulation",
issn = "0009-7322",
publisher = "AHA/ASA",
number = "22",

}

RIS

TY - JOUR

T1 - Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes

AU - Serruys, Patrick W

AU - Onuma, Yoshinobu

AU - Ormiston, John A

AU - de Bruyne, Bernard

AU - Regar, Evelyn

AU - Dudek, Dariusz

AU - Thuesen, Leif

AU - Smits, Pieter C

AU - Chevalier, Bernard

AU - McClean, Dougal

AU - Koolen, Jacques

AU - Windecker, Stephan

AU - Whitbourn, Robert

AU - Meredith, Ian

AU - Dorange, Cécile

AU - Veldhof, Susan

AU - Miquel-Hebert, Karine

AU - Rapoza, Richard

AU - García-García, Hector M

PY - 2010/11/30

Y1 - 2010/11/30

N2 - The first generation of the bioresorbable everolimus drug-eluting vascular scaffold showed signs of shrinkage at 6 months, which largely contributed to late luminal loss. Nevertheless, late luminal loss was less than that observed with bare metal stents. To maintain the mechanical integrity of the device up to 6 months, the scaffold design and manufacturing process of its polymer were modified.

AB - The first generation of the bioresorbable everolimus drug-eluting vascular scaffold showed signs of shrinkage at 6 months, which largely contributed to late luminal loss. Nevertheless, late luminal loss was less than that observed with bare metal stents. To maintain the mechanical integrity of the device up to 6 months, the scaffold design and manufacturing process of its polymer were modified.

KW - Absorbable Implants

KW - Aged

KW - Coronary Angiography

KW - Coronary Stenosis

KW - Coronary Vessels

KW - Drug-Eluting Stents

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Male

KW - Middle Aged

KW - Polymers

KW - Retrospective Studies

KW - Sirolimus

KW - Time Factors

KW - Tissue Scaffolds

KW - Tomography, Optical Coherence

KW - Treatment Outcome

U2 - 10.1161/CIRCULATIONAHA.110.970772

DO - 10.1161/CIRCULATIONAHA.110.970772

M3 - Journal article

C2 - 21098436

VL - 122

SP - 2301

EP - 2312

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 22

ER -